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First trimester maternal serum PAPP-A levels and macrosomia
in nondiabetic mothers
Ebru TARIM, Servet Özden HACIVELİOĞLU, Tayfun ÇOK, Halil Tayfun BAĞIŞ

Aim: To determine whether or not there is a relationship between first-trimester maternal serum pregnancy-associated
placental protein (PAPP-A) levels and fetal macrosomia in nondiabetic mothers.
Materials and methods: In this study, 63 consecutive term macrosomic neonates (Group 1) (birth weight ≥ 4000 g)
and 100 consecutive appropriate-for-gestational-age (AGA) term neonates (Group 2) were included. Transabdominal
ultrasound examinations were performed to diagnose any major fetal defects and to measure crown-rump length (CRL)
and fetal nuchal translucency (NT) thickness. Blood samples were drawn from each woman in order to obtain fasting
blood glucose, PAPP-A, and free beta-human chorionic gonadotropin (beta-hCG) levels. Ultrasound measurements
of the fetal biparietal diameter, abdominal circumference, and femur length were obtained at 29-34 weeks of gestation.
Results: The two groups were similar with respect to maternal age, parity, and gestational age in the first trimester. There
were no significant differences between the groups in terms of the mean plasma levels of PAPP-A, free beta-HCG (as
MoM values), mean CRL, and NT measurements. First-trimester PAPP-A levels were not correlated with birth weight
(r = –0.116, P = 0.146), maternal age (r = 0.137, P = 0.089), maternal body mass index (BMI) in the first trimester (r =
–0.037, P = 0.641) or at delivery (r = 0.042, P = 0.620), fasting blood glucose in the first trimester (r = –0.019, P = 0.816),
macrosomia (r = –0.092, P = 0.249), or the occurrence of male sex (r = –0.074, P = 0.358) by the Pearson and Spearman
correlations. In addition, first-trimester PAPP-A levels were not correlated with ultrasonographic measurements at 2934 weeks of gestation.
Conclusion: Although PAPP-A may promote fetal growth and development through metabolic and differentiation
pathways, it seems that there is no relationship between PAPP-A levels and macrosomia.
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Diyabeti olmayan annelerde gebeliğin ilk üç ayında maternal serum PAPP-A
düzeyleri ve makrozomi
Amaç: Bu çalışmadaki amacımız gebeliğin ilk üç ayındaki maternal serum PAPP-A (gebelikle ilişkili plasental protein)
ve makrozomi arasında ilişkinin olup olmadığını araştırmaktır.
Yöntem ve gereç: Termde doğan 63 makrozomik bebek (doğum kiloları ≥ 4000 g) (Grup 1) ve 100 normal kiloya sahip
bebek (Grup 2) çalışmaya alındı. Fetal major anomalilerin varlığı, baş-popo mesafesi ve ense kalınlıkları ölçümü için
transabdominal ultrasonografi yapıldı. Her kadından kanda açlık kan şekeri, PAPP-A ve serbest beta-hCG düzeyleri
bakıldı. Gebeliğin 29- 34. haftalarında biparietal çap, abdominal çevre ve femur ölçümleri elde edildi.
Bulgular: İki grup arasında anne yaşı, parite ve ilk üç aydaki ultrasonografik gebelik yaşı bakımından fark yoktu.
Gruplar arasında maternal serum PAPP-A, serbest beta-hCG düzeyleri ile fetal baş-popo mesafesi ve ense kalınlıkları
ölçümü yönünden fark izlenmedi. Pearson ve Spearman korelasyon testlerinde; birinci trimester PAPP-A düzeyleri
doğum kilosu (r = –0,116, P = 0,146), maternal yaş (r = 0,137, P = 0,089), annenin birinci trimesterde (r = –0,037, P =
Received: 28.05.2010 – Accepted: 14.09.2010
Department of Obstetrics and Gynecology, Faculty of Medicine, Başkent University, Adana - TURKEY
Correspondence: Ebru TARIM, Department of Obstetrics and Gynecology, Faculty of Medicine, Başkent University, Adana - TURKEY
E-mail: eatarim@hotmail.com

581

PAPP-A and macrosomia

0,641) ve doğumda (r = 0,042, P = 0,620) vücut kitle indeksi, birinci trimesterde açlık kan glukozu (r = –0,019, P = 0,816)
makrozomi (r = –0,092, P = 0,249) ve erkek cinsiyet (r = –0,074, P = 0,358) ile ilişkili bulunmadı. Ek olarak; birinci
trimester PAPP-A düzeyleri gebeliğin 29-34. haftalarındaki ultrasonografi ölçümleri ile de korelasyon göstermedi.
Sonuç: PAPP-A fetal büyüme ve gelişmeyi metabolik ve farklılaşmayı içeren yollar üzerinden arttırsa da, PAPP-A
düzeyleri ve fetal makrozomi arasında bir ilişki yok gibi görünmektedir.
Anahtar sözcükler: PAPP-A, makrozomi, ilk üç ay tarama

Introduction
Pregnancy-associated placental protein A
(PAPP-A), a placental hormone that increases
in the maternal circulation throughout human
pregnancy, has long been recognized as a useful firsttrimester marker for Down’s syndrome (1). PAPP-A
exhibits insulin-like growth factor binding protein
4 (IGFBP-4) protease activity and it regulates the
bioavailability of IGF-II in the local environment
(2). Low levels of PAPP-A are associated with high
levels of IGFBP-4 and, consequently, with low levels
of free IGF-II (3). IGF-II regulates fetal growth by
controlling the uptake of glucose and amino acids in
cultured trophoblasts. It also plays a significant role
in the autocrine and paracrine control of trophoblast
invasion (4,5).
Decreased levels of first-trimester maternal
serum PAPP-A have been found to be predictive for
adverse pregnancy outcome in many studies (3,6-8).
Secondary analysis of the FASTER trial demonstrated
that extremely low levels of PAPP-A were significantly
associated with adverse pregnancy outcomes (9).
Fetal macrosomia is associated with increased
numbers of perinatal complications, such as
prolonged labor, perinatal mortality, asphyxial
injuries, meconium aspiration, shoulder dystocia,
soft tissue trauma, humeral and clavicular fractures,
brachial plexus, and facial palsies (10-13). However,
the accuracy of sonographic estimations of fetal
weight in macrosomia is suboptimal, with a positive
predictive value of just 38%-67% (12).
It is commonly assumed that first-trimester
biological variations in fetal size are minimal and
that variations in size do not emerge until the second
half of pregnancy (14). As macrosomia remains a
significant contributor to perinatal morbidity and
mortality, however, early identification of fetuses at
582

risk for developing growth disorders may assist in
targeting those that warrant more intensive antenatal
surveillance.
In this retrospective study, we investigate the
potential relationship between first-trimester
maternal serum PAPP-A levels and fetal macrosomia.
Materials and methods
This study was conducted at Başkent University,
Adana, Turkey, between January 2008 and June 2009.
Approval for the study was granted by the local ethics
committee. Exclusion criteria included patients
with multiple gestation, preterm delivery, maternal
hypertension or proteinuria, pregestational diabetes,
gestational diabetes, and known genetic or congenital
malformations.
The studied group comprised 63 consecutive
term macrosomic neonates (birth weight ≥ 4000
g) (Group 1), while the control group was made up
of 100 consecutive appropriate-for-gestational-age
(AGA) term neonates (Group 2) (10th percentile <
birth weight < 90th percentile). Based on an effect
size of 0.20, a power level of 0.80, and an alpha level
of 0.05, the minimum sample size was determined as
63 for each group.
Major fetal defects, crown-rump length (CRL), and
nuchal translucency (NT) thickness were determined
by transabdominal ultrasound examination using the
Prosound Alpha 10 (Aloka™) system (15). Gestational
age was based on the mother’s last menstrual period
and ultrasonographic measurements of CRL before 12
weeks of gestation. Ultrasound measurements of the
fetal biparietal diameter, abdominal circumference,
and femur length were obtained at 29-34 weeks
of gestation. The Hadlock nomogram was used to
estimate fetal growth in the third trimester based
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on ultrasonographic measurements of biparietal
diameter (BPD), abdominal circumference (AC),
and femur length (FL) (16,17).
A Kryptor analyzer (Brahms AG, Berlin,
Germany) was used to measure maternal serum levels
of PAPP-A and serum free beta-human chorionic
gonadotropin (beta-hCG). Biochemical analysis
was done on the same day as the NT measurements.
Serum analyte levels were then converted to multiples
of the median (MoM) adjusted for gestational age,
ethnicity, and body mass index (BMI). The screening
for gestational diabetes was done according to the
criteria of Carpenter and Coustan between 24 and 28
weeks of gestation (18).
Data are expressed as mean ± SD. Differences
between the 2 groups were analyzed using the
independent Student’s t-test and the MannWhitney U test. The homogeneity of variances
was calculated by Levene’s test and the Liliefors
significance correction test. Correlations between
the groups were assessed with Pearson and Spearman
correlation coefficient and linear regression analyses.
All statistical calculations were performed using
the program SPSS for Windows, version 9.05 (SPSS
Inc., Chicago, IL, USA). Differences were considered
statistically significant at levels of P < 0.05.

Results
Some clinical and demographic characteristics of
the 2 groups are shown in Table 1. The mean birth
weights of the macrosomic babies were 4173 ± 176
g, compared to 3350 ± 328 g for control group (P
= 0.000). The groups were similar with respect to
maternal age, parity, BMI at the first trimester, and
gestational weeks at delivery. In contrast with these
similarities, BMI at the time of delivery (31.20 ± 3.29
in Group 1 and 29.86 ± 3.59 in Group 2, P = 0.019)
and the percentage of male neonates (71% in Group
1 and 48% in Group 2, P = 0.003) were significantly
higher in the macrosomic group (Table 1).
There were no significant differences between the
groups with respect to gestational age (weeks) in the
first trimester, the mean plasma levels of PAPP-A,
free beta-hCG (as MoM values), the mean CRL, NT
measurements, or mean fasting blood glucose levels
(Table 2).
The linear correlation between PAPP-A levels and
macrosomia, birth weight, and other variables was
calculated. In the Pearson correlation, first-trimester
PAPP-A levels were not correlated with birth weight
(r = –0.116, P = 0.146), maternal age (r = 0.137, P
= 0.089), maternal BMI in the first trimester (r

Table 1. Demographic data of the 2 groups included in the study.
Group 1
(n = 63)

Group 2
(n = 100)

P

28.39 ± 5.09

29.42 ± 4.11

0.161

36 (57.1)

49 (49)

0.336

BMI in the first trimester*

24.86 ± 3.40

23.77 ± 3.60

0.057

BMI at the time of delivery*

31.20 ± 3.29

29.86 ± 3.59

0.019

Gestational weeks at delivery*

39.30 ± 0.94

39.06 ± 0.91

0.109

45 (71 %)

48 (48 %)

0.003

Age*
Parity ≥ 1, n (%)

Male neonates, n (%)
*presented as mean ± SD
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Table 2. Comparison of the groups according to the gestational age in the first trimester, fetal
CRL and NT measurements, maternal serum PAPP-A, free beta-hCG, and fasting
glucose levels.
Group 1
(n = 63)

Group 2
(n = 100)

P

Gestational age (weeks) at the first trimester*

12.59 ± 0.67

12.45 ± 0.59

0.184

CRL (mm)*

63.76 ± 8.64

62.40 ± 8.05

0.311

PAPP-A (MoM)*

0.94 ± 0.51

1.05 ± 0.57

0.211

PAPP-A (mIU/mL)*

2.28 ± 1.59

2.51 ± 1.80

0.407

Free b-hCG (MoM)*

1.19 ± 0.94

1.14 ± 0.66

0.659

NT (mm)*

1.73 ± 0.45

1.83 ± 0.33

0.098

Fasting glucose (mg/dL)*

83.62 ± 9.87

81.152 ± 7.29

0.069

*presented as mean ± SD

= –0.037, P = 0.641) or at delivery (r = 0.042, P =
0.620), or fasting blood glucose in the first trimester
(r = –0.019, P = 0.816). First-trimester PAPP-A
levels were also not correlated with macrosomia (r =
–0.092, P = 0.249) or the occurrence of male sex (r =
–0.074, P = 0.358) by the Spearman correlation.
In addition, first-trimester PAPP-A levels were
not correlated with BPD (r = 0.003, P = 0.976), AC (r
= 0.037, P = 0.663), or FL measurements (r = 0.084, P
= 0.320) by the Pearson correlation (Table 3).

Table 3. Pearson correlation analysis of PAPP-A levels with
different ultrasonographic parameters in the third
trimester.
r

P

BPD (mm)

0.003

0.976

BPD (weeks)

0.007

0.928

AC (mm)

0.037

0.663

AC (weeks)

0.025

0.763

FL (mm)

0.084

0.320

FL (weeks)

0.028

0.731

584

Discussion
Excessive fetal growth can occur because of
genetic factors or because of an increased supply of
nutrients. Fetal hyperglycemia and hyperinsulinemia
promote growth in infants of diabetic mothers
(IDMs) and infants with Beckwith-Wiedemann
syndrome. Macrosomic infants who are not IDMs
exhibit high levels of C-peptide, indicating that
increased insulin secretion in nondiabetic disorders
may also contribute to enhanced fetal growth (19).
Our study showed that neither PAPP-A nor free
beta-hCG levels are associated with an increased
risk of macrosomia in infants born to nondiabetic
patients. This finding contrasts with that of Peterson
and Simhan, who demonstrated an association of
>90th percentile PAPP-A with macrosomia (20).
Canini et al. also found that maternal serum PAPP-A
levels in the late first trimester of pregnancy were
associated with subsequent fetal growth, both in
the form of physiologic variations and in abnormal
growth (21). This is in contrast to the findings of
Habayeb et al., however, which showed that firsttrimester fetal growth rate was not related to birth
weight percentile or first-trimester PAPP-A levels
(22).

E. TARIM, S. Ö. HACIVELİOĞLU, T. ÇOK, H. T. BAĞIŞ

Alterations in the level of PAPP-A are associated
with adverse pregnancy outcomes in chromosomally
normal fetuses. PAPP-A also plays an important
role in biological pathways that promote effective
placentation and fetal growth (7). Low levels of
PAPP-A adversely affect fetal growth due to the
resulting reduction in the levels of free or soluble IGF
in fetal circulation (23). Both clinical and research
evidence has suggested that there is a relation between
IGFs and human fetal growth. (24-26)
Leung et al. found that first-trimester PAPP-A
and free beta-hCG were independent factors that
influence subsequent fetal growth. In that study,
PAPP-A level was positively correlated with femur
length and abdominal circumference in the second
trimester, while free beta-hCG level was negatively
correlated with them. Biparietal diameter was not
affected by either of the hormones, however (27). In
our own study, we were unable to find any correlation
between PAPP-A levels and ultrasonographic
measurements at 29-34 weeks of gestation.

Our findings are limited by the retrospective
design of the study. As the data were collected
from chart reviews, the findings are dependent on
correct entry of the serum analyte levels, maternal
characteristics, and neonatal outcomes.
We conclude by underlining the fact that fetal
growth is a complex process influenced by various
determinants, such as genetics, maternal factors,
the uterine environment, and maternal and fetal
hormones. It appears that many growth factors
(IGF-I, epithelial growth factor, and fibroblast
growth factor-2) and their receptors influence
materno-fetal communication, a communication
that might be implicated in the fetal weight gain of
macrosomic babies (28). Although PAPP-A may
promote fetal growth and development through
metabolic and differentiation pathways, it seems that
there is no relationship between PAPP-A levels and
macrosomia. Further studies are still required to fully
elucidate the interaction between growth factors and
their receptors in macrosomic infants.
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